NOVOLIN 70/30 Drug Profile

Summary for Tradename: NOVOLIN 70/30

High Confidence Patents:	2
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for NOVOLIN 70/30

Recent Clinical Trials for NOVOLIN 70/30

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University of Illinois at Chicago	Phase 2
State University of New York - Downstate Medical Center	Phase 4
University of California, San Francisco	N/A

See all NOVOLIN 70/30 clinical trials

Pharmacology for NOVOLIN 70/30

Established Pharmacologic Class	Insulin
Chemical Structure	Insulin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for NOVOLIN 70/30 Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for NOVOLIN 70/30 Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	NOVOLIN 70/30	insulin isophane human and insulin human	Injection	019991		2009-02-09	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLIN 70/30	insulin isophane human and insulin human	Injection	019991		2014-10-14	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for NOVOLIN 70/30 Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	NOVOLIN 70/30	insulin isophane human and insulin human	Injection	019991		2036-12-20	Patent claims search
Novo Nordisk Inc.	NOVOLIN 70/30	insulin isophane human and insulin human	Injection	019991		2038-12-19	Patent claims search
Novo Nordisk Inc.	NOVOLIN 70/30	insulin isophane human and insulin human	Injection	019991		2037-02-17	Patent claims search
Novo Nordisk Inc.	NOVOLIN 70/30	insulin isophane human and insulin human	Injection	019991		2038-07-09	Patent claims search

International Patents for NOVOLIN 70/30

Country	Patent Number	Estimated Expiration
Slovenia	8910315
Greece	3004398
Germany	69233602
Yugoslavia	31589

Market Dynamics and Financial Trajectory for NOVOLIN 70/30

Last updated: February 19, 2026

What is NOVOLIN 70/30?

NOVOLIN 70/30 is a premixed human insulin used to manage blood glucose levels in diabetics. It combines 70% intermediate-acting NPH insulin and 30% rapid-acting regular insulin. Manufactured by Novo Nordisk, it is approved globally, marketed primarily in North America, Europe, and select emerging markets.

Market Context and Competitive Landscape

Commercialization and Market Share

• Globally, insulin market size exceeded USD 26 billion in 2022, with premixed insulins like NOVOLIN 70/30 accounting for approximately 15-20%.
• Prominent competitors include Eli Lilly's Humulin 70/30, Sanofi’s Mixtard, and other biosimilar equivalents.
• NOVOLIN 70/30 retains significant market share due to established reputation, affordability, and distribution networks.

Regulatory Approvals and Patent Status

• No recent patent protections restrict NOVOLIN 70/30 for original formulations post-2020.
• Marketing approvals span the US (via FDA), European Union (EMA), and other jurisdictions.
• Biosimilar entries in recent years threaten its market dominance but have faced market entry barriers related to manufacturing complexity and physician familiarity.

Pricing and Reimbursement Landscape

• Average wholesale price (AWP) varies by region: USD 70-80 per 10 mL vial in North America.
• Reimbursement policies favor affordable insulins; Medicaid and national health plans often negotiate discounts.
• Price erosion is ongoing due to biosimilar competition, especially in developed markets.

Market Dynamics

Drivers

• Increasing incidence of diabetes: WHO estimates global adult prevalence at 422 million as of 2014, projected to grow.
• Growing adoption of premixed insulins among type 2 diabetics for convenience.
• Cost-sensitive markets prioritize affordable options like NOVOLIN 70/30.

Restraints

• Shift toward basal-bolus regimens favors flexible insulin analogs.
• Patient preferences for flexible dosing reduce demand for fixed premixed formulations.
• Biosimilar entry reduces pricing power.

Opportunities

• Expansion into emerging markets with rising diabetes rates.
• Developing patient-friendly delivery devices.
• Formulation innovations to improve pharmacokinetics.

Threats

• Biosimilar competition: Several approved insulin biosimilars reduce market margins.
• Regulatory hurdles in certain markets.
• Healthcare providers shifting toward newer insulin analogs.

Financial Trajectory Forecast

Revenue Projections (2023-2027)

Year	Estimated Global Sales (USD billion)	CAGR	Key Factors
2023	1.2	3%	Mature market, stable demand in key regions
2024	1.24	3.3%	Market penetration in emerging economies
2025	1.3	4.2%	Increased access, biosimilar competition stabilizes
2026	1.36	4.6%	Innovation-driven growth, expanded distribution
2027	1.42	4.8%	Increasing demand in low- to middle-income countries

Profitability Outlook

• Gross margins estimated at 65-70%, influenced by regional pricing and biosimilar competition.
• Operating margins likely to decline from 20% to 15% due to price pressures.
• R&D investments focus on next-generation formulations and delivery systems.

Investment Considerations

• Nova Nordisk’s ongoing biosimilar pipeline could impact NOVOLIN 70/30 revenues.
• Strategic expansion into emerging markets offers upside.
• Cost management and innovation could help sustain margins.

Conclusion

NOVOLIN 70/30 maintains a competitive position in the premixed insulin segment, with stable but modest growth expected over the next five years. Market expansion hinges on balancing competitive pressures from biosimilars and new insulin analogs against ongoing demand in cost-sensitive and emerging markets.

Key Takeaways

• Market size of USD 26 billion in 2022, with 15-20% attributed to premixed insulins.
• Revenue growth projected at approximately 3-5% annually through 2027.
• Biosimilar competition remains the primary threat, constraining pricing and margins.
• Expansion into emerging markets offers the most significant growth opportunity.
• Ongoing innovation necessary to counteract shifting prescribing patterns.

FAQs

1. How does NOVOLIN 70/30 compare to insulin analogs?
It offers a fixed combination of intermediate- and rapid-acting insulin, providing convenience but less flexibility than basal-bolus regimens with insulin analogs.

2. What factors influence its pricing?
Pricing is impacted by regional healthcare policies, reimbursement negotiations, manufacturing costs, and biosimilar competition.

3. Which markets are driving growth for NOVOLIN 70/30?
Emerging markets in Asia, Latin America, and Africa are experiencing increased insulin adoption, supporting growth.

4. How will biosimilar products impact NOVOLIN 70/30?
Biosimilars are likely to exert downward pressure on prices, shrinking margins and potentially market share.

5. What innovation strategies could enhance its market position?
Developing user-friendly delivery devices and formulations with improved pharmacokinetics could bolster demand.

---

References

[1] International Diabetes Federation. (2019). IDF Diabetes Atlas, 9th ed.
[2] IQVIA. (2022). Global insulin market analysis.
[3] U.S. Food and Drug Administration. (2022). Approved biosimilars.
[4] European Medicines Agency. (2022). Biosimilar insulin approvals.
[5] MarketWatch. (2023). Insulin market report.